David J. Matlin - Jun 16, 2023 Form 4 Insider Report for Clene Inc. (CLNN)

Role
Director
Signature
/s/ Jerry Miraglia POA
Stock symbol
CLNN
Transactions as of
Jun 16, 2023
Transactions value $
$1,200,000
Form type
4
Date filed
6/20/2023, 07:57 AM
Previous filing
May 5, 2023
Next filing
Aug 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLNN Common Stock Purchase $1.2M +1.5M +28.34% $0.80 6.79M Jun 16, 2023 Direct
holding CLNN Common Stock 150K Jun 16, 2023 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLNN Warrants (Right to buy) Award +1.5M 1.5M Jun 16, 2023 Common Stock 1.5M $1.50 Direct F2, F3
transaction CLNN Warrants (Right to buy) Award +1.5M 1.5M Jun 16, 2023 Common Stock 1.5M $1.10 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are owned by the Matlin Family Trust 2020. Mr. Matlin in the trustee of the Matlin Family Trust 2020. The shares owned by the Matlin Family Trust 2020 may be deemed to be beneficially owned by Mr. Matlin.
F2 The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant.
F3 The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.
F4 The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.